P McEwan

436 total citations
18 papers, 316 citations indexed

About

P McEwan is a scholar working on Endocrinology, Diabetes and Metabolism, Neurology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, P McEwan has authored 18 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Endocrinology, Diabetes and Metabolism, 3 papers in Neurology and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in P McEwan's work include Diabetes Treatment and Management (4 papers), Diabetes Management and Research (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). P McEwan is often cited by papers focused on Diabetes Treatment and Management (4 papers), Diabetes Management and Research (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). P McEwan collaborates with scholars based in United Kingdom, Canada and France. P McEwan's co-authors include M. F. Scanlon, Andrew Palmer, Ian B. Wilkinson, Margaret M. Holmes, Michael P.T. Gillett, Jane Brown, Stephen W. Sorensen, Richard Kahn, Ruth L. Coleman and Philip Clarke and has published in prestigious journals such as Diabetes Care, American Journal of Hypertension and Value in Health.

In The Last Decade

P McEwan

17 papers receiving 303 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P McEwan United Kingdom 5 168 97 85 42 38 18 316
Michelle D. Kelsey United States 9 67 0.4× 93 1.0× 53 0.6× 20 0.5× 85 2.2× 23 286
Helmut Wenzel Germany 9 177 1.1× 79 0.8× 55 0.6× 54 1.3× 22 0.6× 32 323
Wendy S. Klittich United States 7 83 0.5× 47 0.5× 185 2.2× 59 1.4× 135 3.6× 14 344
Anita G. Au Canada 8 62 0.4× 134 1.4× 41 0.5× 59 1.4× 91 2.4× 9 369
Kirsi Norrbacka United States 13 301 1.8× 45 0.5× 62 0.7× 23 0.5× 42 1.1× 32 385
Dori Bilik United States 7 209 1.2× 29 0.3× 82 1.0× 89 2.1× 73 1.9× 8 402
Ashley Galloway United States 8 56 0.3× 99 1.0× 86 1.0× 22 0.5× 117 3.1× 11 288
Venkatesan Vidi United States 7 102 0.6× 158 1.6× 35 0.4× 9 0.2× 53 1.4× 12 351
E. J Wallis United Kingdom 4 134 0.8× 154 1.6× 86 1.0× 30 0.7× 125 3.3× 6 343
Xuxu Rao China 8 147 0.9× 197 2.0× 18 0.2× 64 1.5× 82 2.2× 19 413

Countries citing papers authored by P McEwan

Since Specialization
Citations

This map shows the geographic impact of P McEwan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P McEwan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P McEwan more than expected).

Fields of papers citing papers by P McEwan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P McEwan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P McEwan. The network helps show where P McEwan may publish in the future.

Co-authorship network of co-authors of P McEwan

This figure shows the co-authorship network connecting the top 25 collaborators of P McEwan. A scholar is included among the top collaborators of P McEwan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P McEwan. P McEwan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Gordon, Jason, et al.. (2014). Weight gain, hypoglycaemia and cost-effectiveness: What drives value among type 2 diabetes treatments in the short term. Value in Health. 17(3). A251–A251. 1 indexed citations
2.
Foos, V., James L. Palmer, David Grant, et al.. (2012). PRM58 Long-Term Validation of the IMS CORE Diabetes Model in Type 1 and Type 2 Diabetes. Value in Health. 15(7). A470–A470. 10 indexed citations
3.
McEwan, P & M. Lebmeier. (2012). PUK22 Evaluating the Minimum Renal Allograft Survival Time Required for Transplantation to Remain Cost Saving in the UK. Value in Health. 15(7). A459–A459. 1 indexed citations
4.
Palmer, James L., et al.. (2012). PDB18 Direct Medical Costs of Diabetes Mellitus in China: Annual Cost of Illness and Long-Term Projections Using a Validated Diabetes Model. Value in Health. 15(7). A662–A662. 2 indexed citations
5.
Morgan, Christopher Ll., et al.. (2010). A longitudinal study into the new and long-term use of self-monitoring blood glucose strips in the UK. Diabetes Therapy. 1(1). 1–9. 8 indexed citations
6.
Bergenheim, Klas, et al.. (2010). PDB44 THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS SULFONYLUREA (SU) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY. Value in Health. 13(7). A291–A292. 1 indexed citations
7.
Kolasa, Katarzyna, et al.. (2010). PDB37 THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS NPH INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN POLAND. Value in Health. 13(7). A290–A290. 1 indexed citations
8.
9.
Palmer, Andrew, Valentine Wn, P McEwan, et al.. (2007). 'Computer modeling of diabetes and its complications: A report on the Fourth Mount Hood Challenge Meeting'. Diabetes Care. 30(6). 1638–1646. 178 indexed citations
10.
Jaime, J., et al.. (2007). Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model. Journal of Medical Economics. 10(3). 239–254. 21 indexed citations
11.
12.
Cockcroft, Jeremy K., Ian B. Wilkinson, Mark L. Evans, et al.. (2005). Pulse Pressure Predicts Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus. American Journal of Hypertension. 18(11). 1463–1467. 78 indexed citations
13.
14.
Morgan, CL, et al.. (2005). PDB1 DIABETIC PERIPHERAL NEUROPATHY: EVALUATION OF THE INTER-ASSOCIATION BETWEEN THE RANGES OF NEUROPATHIC SYMPTOMS. Value in Health. 8(6). A154–A154. 2 indexed citations
15.
16.
Dixon, Simon, et al.. (2004). PHP15 INCLUDING CARER UTILITY IN ECONOMIC EVALUATIONS: A PRELIMINARY ANALYSIS OF THE IMPLICATIONS FOR FUNDING THRESHOLDS. Value in Health. 7(3). 371–371. 1 indexed citations
17.
McEwan, P, et al.. (2000). Evaluating the Framingham risk equations for predicting heart disease (CHD) in type 2 diabetes. ORCA Online Research @Cardiff (Cardiff University). 1 indexed citations
18.
McEwan, P, et al.. (1990). Failure of bicycle exercise electrocardiograms to predict major post-operative cardiac complications in patients undergoing abdominal aortic surgery.. PubMed. 83(2). 65–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michelle D. Kelsey Breakdown of academic impact, for papers by Helmut Wenzel Breakdown of academic impact, for papers by Wendy S. Klittich Breakdown of academic impact, for papers by Anita G. Au Breakdown of academic impact, for papers by Kirsi Norrbacka Breakdown of academic impact, for papers by Dori Bilik Breakdown of academic impact, for papers by Ashley Galloway Breakdown of academic impact, for papers by Venkatesan Vidi Breakdown of academic impact, for papers by E. J Wallis Breakdown of academic impact, for papers by Xuxu Rao
Rankless by CCL
2026